Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
There is a critical need for safe and effective drugs for COVID‐19. Only remdesivir has received authorization for COVID‐19 and has been shown to improve outcomes but not decrease mortality. However, the dose of remdesivir is limited by hepatic and kidney toxicity. ACE2 is the critical cell surface...
Uložené v:
| Vydané v: | EMBO molecular medicine Ročník 13; číslo 1; s. e13426 - n/a |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
Nature Publishing Group UK
11.01.2021
EMBO Press John Wiley and Sons Inc Springer Nature |
| Predmet: | |
| ISSN: | 1757-4676, 1757-4684, 1757-4684 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
Buďte prvý, kto okomentuje tento záznam!